Category Archives: Mesenchymal Stem Cells

Hyalofast One Step Technique - Arthroscopy implantation Hyalofast acts as a scaffold for bone marrow aspirate or as a chondroprotective coverage which allows in situ residence of mesenchymal stem cells and other a... By: CIMED Healthcare … Continue reading →

Freeport, Grand Bahama (PRWEB) November 25, 2014 Okyanos, the leader in cell therapy, announced the adoption of body-jet eco for use in the harvesting of adult stem cells for use in cell therapy. The Okyanos procedure begins with the extraction of a small amount of body fat, a process done using advanced water-jet assisted liposuction technology. The body-jet eco system is utilized during this procedure and allows a larger number of viable adult stem cells to be harvested. After separating the cells from fat tissue, the Okyanos medical doctor immediately injects these cells into and around the area needing treatment allowing targeting of the cells to repair damaged tissue. According to Dr. Todd Malan, Chief Cell Therapy Officer and General Surgeon at Okyanos, who was involved in helping develop the appropriate settings of the body-jet eco use in adult stem cell harvesting, The body-jet eco was used during our first stem cell procedure at Okyanos. It performed flawlessly as expected and we feel it meets our tough standards. This is much gentler and more precise, making the overall procedure faster with less trauma to the surrounding tissue and less diversion of the adult stem cells from the intended area. The … Continue reading →

Friedenstein AJ, Chailakhjan RK, Lalykina KS: The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970, 3:393-403. PubMedAbstract Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147. PubMedAbstract | PublisherFullText Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, et al.: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49. PubMedAbstract | PublisherFullText Simmons PJ, Torok-Storb B: Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991, 78:55-62. PubMedAbstract Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, Simmons PJ: Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003, 116:1827-1835. PubMedAbstract | PublisherFullText Originally posted here: Arthritis Research & Therapy | Full text | Mesenchymal ... … Continue reading →

By: Adam Feuerstein | 11/18/14 - 10:16 AM EST Inject a cocktail of undifferentiated stem cellsinto a patient who has suffered a heart attack, and days or even weekslater, the stem cells transform into cardiac cells and rebuild the damaged heart muscle. Months later, the patient has a "new" healthy heart.It's a great story. But so far, the proof remains elusive though not for a lack of trying. The latest company to fulfill this ambitious scenario is NeoStem (NBS) which presented disappointing (but not surprising) results from a small study of its proprietary cardiac stem-cell therapy NBS10 at the American Heart Association annual meeting Monday. NeoStem tried to put some positive spin on the bad news but shares are down 25% to $5.10. NBS10, formerly known as AMR-001, is an autologous stem-cell therapy derived from a patient's own bone marrow. When injected back into patients following a heart attack, the stem cells are supposed torestore blood flow, rebuild damaged cardiac muscle and improve function. Except in NeoStem's study, NBS10 fell short on two primary endpoints designed to assess the therapy's efficacy. The study used non-invasive imaging to assess blood flow through the heart, six months after a single infusion of … Continue reading →

You no longer have to be Rich and famous to experience the Profound Healing effects and Intense Revitalizing and Anti-Aging benefits of MFIII (MF3) Live Cell Therapy - the best anti-aging product available in the world! Thanks to Swiss innovation and Technology, this amazing anti-aging product is now available for the first time in 70 years, and some refer to this scientific breakthrough in anti-aging and looking young as the Stem Cell in a Capsule. Whether you are sick or experiencing chronic fatigue or just seeking the best Anti-aging and Skin Beauty supplement, everyone will benefit from the rejuvenation and regeneration of MFIII of Switzerland Live Cell Therapy. Best of all, it's acompletely Natural and Safe anti-aging solution, facilitatating and enhancing the body's ability to heal itself naturally, free from any side effects. At last, you can feel younger, reduce cellular aging and feel full of vitality, energy, and dynamism in around 3-6 weeks with MFIII Switzerland hi-tech oral supplement formulation. MF III ( MF3) Sheep and Vegetal Placenta helps to awaken dormant cells inside the body, thereby enhancing the expression and function of existing cells, revitalizing and regenerating old and malfunctioning cells. This amazing anti-aging supplement offers what vitamins, … Continue reading →

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber G, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802. PubMedAbstract | PublisherFullText Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002, 20:3404-3412. PubMedAbstract | PublisherFullText Xenidis N, Perraki M, Androulakis N, Kouroussis C, Christophylakis C, Argyraki K, Stathopoulos S, Georgoulias V, Mavroudis D: Predictive and Prognostic Value of Peripheral Blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time Polymerase Chain Reaction in Node-Negative Breast Cancer Patients. J Clin Oncol 2006, 24:3756-3762. PubMedAbstract | PublisherFullText Ignatiadis M, Georgoulias V, Mavroudis D: Micrometastatic disease in breast cancer: clinical implications. Eur J Cancer 2008, 44:2726-2736. PubMedAbstract | PublisherFullText Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K: … Continue reading →

Scientists at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) and their collaborators have developed a scoring scheme that predicts the ability of cancer cells to spread to other parts of the body, a process known as metastasis. This system, which is the first of its kind, opens up the possibility to explore new treatments that suppress metastasis in cancer patients. The findings were published in EMBO Molecular Medicine in September. Led by Professor Jean Paul Thiery, Senior Principal Investigator, and Dr Ruby Huang, Principal Associate, both from CSI Singapore, the scientists developed a scoring scheme which monitors the epithelial-mesenchymal transition (EMT) mechanism. This process was shown to play a role in a large number of cancer-related events, including cancer invasion, metastasis, and chemo-resistance. To date, there are no existing tools to systematically quantify the EMT status of tumors. The newly-developed EMT scoring is thus a promising, versatile tool for investigating EMT roles and dynamics in the progression, treatment response and survival across different types of cancer. It can also be integrated with other molecular tests, such as the detection of mutations of cancer genes, to help identify patients at higher risks for … Continue reading →

By C. Rajan, contributing writer Researchers at Lund University in Sweden have made a major breakthrough in Parkinson's disease treatment by developing stem cell-derived brain cells that can replace the cells lost due to the disease, thus paving the way for the first stem cell transplant treatment for Parkinsons patients. Parkinson's disease, which affects about 10 million people worldwide, is a degenerative nervous system condition which causes tremors, muscle weakness, stiffness, and loss in mobility. Parkinson's is caused by loss of dopamine-producing neurons in the brain. Dopamine is an essential neurotransmitter that is required for regulating movement and emotions. In this study, for the first time ever, the researchers were able to convert human embryonic stem cells into dopamine producing neurons, which behaved like native dopamine cells lost in the disease. The study was led by Malin Parmar, associate professor in Lund's Department of Medicine, and conducted at both Lund University and at MIRCen in Paris as part of the EU networks NeuroStemCell and NeuroStemcellRepair. According to Medical News Today, the researchers produced rat models of Parkinson's disease by destroying the dopamine cells in one part of the rat's brain, and then they transplanted the new dopamine producing stem cell … Continue reading →

PUBLIC RELEASE DATE: 13-Nov-2014 Contact: Krista Conger kristac@stanford.edu 650-725-5371 Stanford University Medical Center @sumedicine A protein that plays a critical role in preventing the development of many types of human cancers has been shown also to inhibit a vital stem cell property called pluripotency, according to a study by researchers at the Stanford University School of Medicine. Blocking expression of the protein, called retinoblastoma, in mouse cells allowed the researchers to more easily transform them into what are known as induced pluripotent stem cells, or iPS cells. Pluripotent is a term used to describe a cell that is similar to an embryonic stem cell and can become any tissue in the body. The study provides a direct and unexpected molecular link between cancer and stem cell science through retinoblastoma, or Rb, one of the best known of a class of proteins called tumor suppressors. Although Rb has long been known to control the rate of cell division, the researchers found that it also directly binds and inhibits the expression of genes involved in pluripotency. "We were very surprised to see that retinoblastoma directly connects control of the cell cycle with pluripotency," said Julien Sage, PhD, associate professor of pediatrics and … Continue reading →

Dr Saw Khay Yong Stem Cell Therapy for the Musculoskeletal System By: Admin KLSMC … Continue reading →